Despite the threat of a 200% tariff, most pharma stocks remained stable. US President Donald Trump’s 200% tariff threat on the pharmaceutical industry is a “shock” that will reverberate through global ...

MediView has announced the first patient enrolment in a study to assess the XR90 Holographic Surgical Navigation system.

Companion Spine has entered a definitive agreement to acquire Paradigm Spine’s business and assets from Xtant Medical Holdings.

The US Food and Drug Administration (FDA) has granted 510(k) clearance for Mendaera’s Focalist, a handheld robotic system.